The Chatter We Make

In mid-December 2019, a policy statement was issued by the USPTO, NIST, and DOJ to clearly state injunctive relief (among other remedies) is available to holders of standard-essential patents (SEPs.)

Gilead's vaccine against the Ebola virus, Remdesivir, is proving effective in combating COVID-19, according to news reports and clinical trials.

This fall, a jury ordered Wells Fargo to pay USAA $200 million for infringing on patents relating to mobile image capture technology. Judging by even more recent "Wells Fargo must pay a fine" news, their patent issues may be the least of their concerns, but it will not likely be the end of the story here.

President Trump has a reputation for unorthodox approaches. His administration's foray into patent enforcement is no exception. 

After graduating from engineering school, I remember speaking to my grandfather, who had worked as a chemical engineer for GE for his entire career after WWII.

Sometimes a patent does not make business sense. It’s a conversation I have frequently with potential and existing clients, and after a brief discussion, drawing attention to important issues they should consider, they often arrive at the conclusion that it’s not worth it.

When your idea is really, really good, it’s almost inevitable that someone is going to copy it. Retroactive legal action is difficult and expensive, so follow these patent tips to get ahead of product copycats, knockoffs, and fast followers.

Clients see a competing product with similar functionality to their own and immediately believe it’s a copy, even if the competitor developed the functionality independently. At that point, they don’t care how the attorneys deal with the situation — the attorneys are expected to find a way to shut down the knockoff.